Dr. Reddy’s to Acquire a Portfolio of 42 Abbreviated New Drug Applications (ANDA) in the US

 Dr. Reddy’s to Acquire a Portfolio of 42 Abbreviated New Drug Applications (ANDA) in the US

Dr. Reddy’s to Acquire a Portfolio of 42 Abbreviated New Drug Applications (ANDA) in the US

Shots:

  • Dr. Reddy’s acquires a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the US, including >30 generics injectable
  • The focus of the acquisition is to enhance Dr. Reddy’s injectable portfolio in the US and globally
  • Dr. Reddy’s will launch the products within the next one to two years and according to IQVIA the products produced ~$645M revenue in 2018 in the US 

Click here to read full press release/ article | Ref: Dr. Reddy’s | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post